|
11 Nov 2020 |
Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R)* (Ustekinumab)
|
|
10 Nov 2020 |
First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
|
|
10 Nov 2020 |
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
|
|
10 Nov 2020 |
Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
|
|
10 Nov 2020 |
Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)
|
|
10 Nov 2020 |
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2
|
|
10 Nov 2020 |
American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV
|
|
10 Nov 2020 |
Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections
|
|
10 Nov 2020 |
Medikine to Present Breakthrough Discoveries of Peptide-Based Agonists of IL-7 and IL-2/15 Receptors at SITC 2020
|
|
10 Nov 2020 |
Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
10 Nov 2020 |
Seven and Eight Biopharma Presents Promising Interim Phase 1 Results for BDB001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
|
|
10 Nov 2020 |
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis
|
|
10 Nov 2020 |
Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2
|
|
10 Nov 2020 |
Medigene's MAGE-A4-specific TCR-Ts detect and fight cancer cells independent of CD8 co-receptor
|
|
10 Nov 2020 |
Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients
|
|
10 Nov 2020 |
Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
|
|
10 Nov 2020 |
Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets
|
|
10 Nov 2020 |
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
|
|
10 Nov 2020 |
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
|
|
10 Nov 2020 |
Tezepelumab NAVIGATOR Phase III trial met primary endpoint of a statistically significant and clinically meaningful reduction in exacerbations in a broad population of patients with severe asthma
|
